Development of cannabidiol as a treatment for severe childhood epilepsies

Williams, C. ORCID: https://orcid.org/0000-0003-4452-671X and Stephens, G. ORCID: https://orcid.org/0000-0002-8966-4238 (2020) Development of cannabidiol as a treatment for severe childhood epilepsies. British Journal of Pharmacology, 177 (24). pp. 5509-5517. ISSN 0007-1188 doi: 10.1111/bph.15274

Abstract/Summary

In recent years there has been a growing appreciation by regulatory authorities that cannabis-based medicines can play a useful role in disease therapy. Although often conflagrated by proponents of recreational use, the legislative rescheduling of cannabis-derived compounds, such as cannabidiol (CBD), has been associated with the steady increase in the pursuit of use of medicinal cannabis. One key driver in this interest has been the scientific demonstration of efficacy and safety of CBD in randomised, placebo-controlled clinical trials in children and young adults with difficult-to-treat epilepsies, which has encouraged increasing numbers of human trials of CBD for other indications and in other populations. The introduction of CBD as the medicine Epidiolex in the US (in 2018) and as Epidyolex in the EU (in 2019) as the first cannabis-derived therapeutic for the treatment for seizures was underpinned by preclinical research performed at the University of Reading. This work was awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019 and is discussed in the following review article.